BOARD OF DIRECTORS

Michael Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank. Prior to this, he was the Chief Financial Officer of Trek Therapeutics, a development stage pharmaceutical company. Mr. Bator served as Managing Director of Healthcare Research at Jennison Associates, a U.S. mutual and pension fund management company that currently manages $175 billion in assets. During his 14 years at Jennison, Mr. Bator evaluated and recommended a wide array of investments in medical devices, European pharmaceuticals, managed care companies, and many others including well-known companies such as Medtronic, Abbott, Baxter, Johnson and Johnson, Novartis, AstraZeneca, Roche and GSK. Mr. Bator also has extensive management consulting experience, having spent many years with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University.

Dr. Phillip Chan has served as CEO of CytoSorbents Corporation since 2009. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the top performing and largest early stage investors in the greater New York region. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ advanced lipoplasty system in the U.S. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University. In 2012, Dr. Chan was named an Ernst & Young New Jersey Entrepreneur-of-the-Year finalist.

Edward Jones, MD, MBA was an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital prior to his retirement in 2020. Dr. Jones was a practicing nephrologist as well as Medical Director of a dialysis facility for Fresenius Medical Care. He taught renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine. Dr. Jones is a highly respected member of the renal research community.
He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He has been a member of the Renal Physicians Association, the Philadelphia County Medical Society for 17 years and is a past board member of the National Kidney Foundation of the Delaware Valley. Dr. Jones is past-President of the Renal Physicians Association.

Ms. Kim is currently a Vice President at Zimmer Biomet, where she serves as the general manager of the Smart Implants portfolio and is responsible for leading the end-to-end program and product management for Zimmer Biomet’s Smart Implants technology in the orthopedic field. Previously, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Depression at LivaNova from 2020 to 2021. Prior to LivaNova, from 2011 to 2020, Ms. Kim served in increasing roles of responsibility at Johnson & Johnson Medical Devices. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences.

Alan D. Sobel was previously the Managing Member of Sobel & Co., LLC, a Livingston, NJ based full-service accounting, auditing, taxation, and business consulting firm with a diverse clientele including small and mid-sized businesses, non-profit agencies, SEC-registered companies, and individuals, prior to its acquisition by CliftonLarsonAllen LLP (CLA) – the 8th largest accounting firm in the United States. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, amongst others. Alan is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. He earned a Bachelor of Science degree in Accountancy from Bentley College, and a Master of Science in Taxation from Fairleigh Dickinson University.

Mr. Rubin was a founder, Board Director, trusted advisor, and friend of CytoSorbents. Though his untimely passing in 2014 deeply saddened us, his countless contributions to this Company will not be forgotten.
For more about Mr. Rubin and his contributions, please see: Joseph Rubin – In Memoriam.